← back to search

Matthias Gromeier

Duke University · US
Area of research
Genetics · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Virus-based gene therapy research, Viral Infections and Immunology Research, CAR-T cell therapy research, and Viral gastroenteritis research and epidemiology.
h-index
46
citations
6,104
works
179
NIH funding
primary concept
Medicine
email

Recent publications

Data from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 1position: contributordoi
Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.
2026cited by 0position: contributordoi
Supplementary Figure S5 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Table S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Figure S4 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Figure S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Figure S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Table S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Figure S6 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Supplementary Table 1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris
2026cited by 0position: contributordoi
Supplementary Figure S1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026cited by 0position: contributordoi
Polio virotherapy provokes MDA5 signaling and CD4<sup>+</sup> T cell help to mediate cancer <i>in situ</i> vaccination.
2025cited by 1position: contributordoi
Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma
Translational Oncology 2024cited by 6position: middledoi
Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS
Neuro-Oncology 2023cited by 21position: lastdoi
Intratumor childhood vaccine-specific CD4<sup>+</sup> T-cell recall coordinates antitumor CD8<sup>+</sup> T cells and eosinophils
Journal for ImmunoTherapy of Cancer 2023cited by 8position: lastdoi
Early enterovirus translation deficits extend viral RNA replication and elicit sustained MDA5-directed innate signaling.
2023cited by 2position: contributordoi
PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling.
2022cited by 8position: contributordoi
CD155 is a putative therapeutic target in medulloblastoma
Clinical & Translational Oncology 2022cited by 7position: middledoi
Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Induces Diffuse Microglia Activation
2022cited by 1position: contributordoi
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
2021cited by 102position: contributordoi
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.
2021cited by 60position: contributordoi
Enterovirus 2A<sup>pro</sup> Cleavage of the YTHDF m<sup>6</sup>A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling.
2021cited by 25position: contributordoi
CReP mediates selective translation initiation at the endoplasmic reticulum.
2020cited by 18position: contributordoi
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY
Neuro-Oncology 2013cited by 3position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 20 papers (2020–2026)Michael C. Brown · Duke University20 papers (2021–2026) · 16 papers (2021–2026)Darell D. Bigner · Duke Medical Center14 papers (2022–2026) · 12 papers (2022–2026)Zachary P. McKay · Duke University12 papers (2026–2026)Griffin P. Carter · Duke University12 papers (2026–2026)Mark A. Katz · Duke University12 papers (2026–2026)David Ashley · ABS Consulting (United States)11 papers (2026–2026) · 11 papers (2026–2026)Vaibhav Jain · Duke University Hospital11 papers (2026–2026)Andrea L. Ludwig · Heinrich Heine University Düsseldorf11 papers (2026–2026)Annick Desjardins · Duke University Health System11 papers (2026–2026)Stephanie Arvai · Duke Medical Center11 papers (2026–2026) · 11 papers (2026–2026)Georgia Howell · Duke University11 papers (2026–2026)Madison L. Shoaf · Duke University11 papers (2026–2026)Simon G. Gregory · Duke Medical Center11 papers (2026–2026)Dirk P. Dittmer · University of North Carolina at Chapel Hill11 papers (2026–2026)Jonathan P. Kastan · Cold Spring Harbor Laboratory3 papers (2020–2022)